Publications by authors named "Stephen Chia"

100Publications

Impact of wait time from neoadjuvant chemotherapy to surgery in breast cancer: Does time to surgery affect patient outcomes? : Time from Neoadjuvant Chemotherapy to Surgery.

Breast Cancer Res Treat 2020 Dec 1;184(3):755-762. Epub 2020 Oct 1.

BC Cancer Agency, Vancouver Centre, 600 West 10th Avenue, Vancouver, BC, V5Z 4E6, Canada.

View Article and Find Full Text PDF
December 2020

A Matrilineal Genetic Perspective of Hanging Coffin Custom in Southern China and Northern Thailand.

iScience 2020 Apr 5;23(4):101032. Epub 2020 Apr 5.

State Key Laboratory of Genetic Resources and Evolution, Kunming Institute of Zoology, Chinese Academy of Sciences, Kunming 650223, China; Center for Excellence in Animal Evolution and Genetics, Chinese Academy of Sciences, Kunming 650223, China. Electronic address:

View Article and Find Full Text PDF
April 2020

Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer.

N Engl J Med 2020 02 11;382(6):514-524. Epub 2019 Dec 11.

From the David Geffen School of Medicine at UCLA, Los Angeles (D.J.S.); Multidisciplinary Breast Center, Universitair Ziekenhuis Leuven, Leuven (P.N.), and Centre Hospitalier Universitaire Liège and Liege University, Liege (G.J.) - all in Belgium; the British Columbia Cancer Agency, Vancouver, Canada (S.C.); University Hospital Erlangen, Comprehensive Cancer Center Erlangen-European Metropolitan Region of Nuremberg, and Department of Gynecology and Obstetrics, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen (P.A.F.), and the Practice for Hematology and Internal Oncology, Velbert (A.N.) - all in Germany; Istituto Nazionale Tumori Fondazione G. Pascale, Naples (M.D.L.), and Fondazione IRCCS Istituto Nazionale dei Tumori, Milan (G.V.B.) - both in Italy; Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Seoul, South Korea (S.-A.I.); Masaryk Memorial Cancer Institute, Brno, Czech Republic (K.P.); New York University Langone Health, New York (F.J.E.); Instituto de Investigación Sanitaria Gregorio Marañon, Centro de Investigación Biomédica en Red de Cáncer, Grupo Español de Investigación en Cáncer de Mama, Universidad Complutense, Madrid (M.M.), and Hospital Universitario Virgen Macarena, Department of Medicine, Universidad de Sevilla, Seville (L.D.C.-M.) - both in Spain; Netherlands Cancer Institute-Borstkanker Onderzoek Groep Study Center, Amsterdam (G.S.S.); Highlands Oncology Group, Fayetteville, AR (J.T.B.); Institut Régional du Cancer, Strasbourg, France (X.P.); Novartis Pharmaceuticals, East Hanover, NJ (M.S., A.C., K.R.-L.); and Novartis Pharma, Basel, Switzerland (Y.W., T.T.).

View Article and Find Full Text PDF
February 2020

Cancer screening and prevention in BRCA mutation carriers: a missed opportunity?

Br J Cancer 2019 07 7;121(1):1-2. Epub 2019 Jun 7.

Department of Medical Oncology, British Columbia Cancer Agency, 600 West 10th Avenue, Vancouver, BC, V5Z 4E6, Canada.

View Article and Find Full Text PDF
July 2019

TIM-3 expression in breast cancer.

Oncoimmunology 2018;7(11):e1502128. Epub 2018 Aug 23.

Genetic Pathology Evaluation Centre, University of British Columbia, Vancouver, Canada.

View Article and Find Full Text PDF
August 2018

Understanding adjuvant endocrine therapy persistence in breast Cancer survivors.

BMC Cancer 2018 Jul 11;18(1):732. Epub 2018 Jul 11.

School of Population and Public Health, University of British Columbia, V2206 East Mall, Vancouver, BC, V6T 1Z3, Canada.

View Article and Find Full Text PDF
July 2018

Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: MONALEESA-3.

J Clin Oncol 2018 08 3;36(24):2465-2472. Epub 2018 Jun 3.

Dennis J. Slamon, University of California Los Angeles Medical Center, Santa Monica, CA; Patrick Neven, Multidisciplinary Breast Centre, Universitair Ziekenhuis, Leuven; Guy Jerusalem, Centre Hospitalier Universitaire de Liege and Liege University, Liège, Belgium; Stephen Chia, British Columbia Cancer Agency, Vancouver, British Columbia, Canada; Peter A. Fasching, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen; Arnd Nusch, Practice for Hematology and Internal Oncology, Velbert, Germany; Michelino De Laurentiis, Istituto Nazionale Tumori "Fondazione G. Pascale," Naples; Giulia Val Bianchi, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico, Istituto Nazionale dei Tumori, Milan, Italy; Seock-Ah Im, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Republic of Korea; Katarina Petrakova, Masaryk Memorial Cancer Institute, Brno, Czech Republic; Francisco J. Esteva, New York University Langone Health, New York, NY; Miguel Martín, Instituto de Investigacion Sanitaria Gregorio Marañon, Centro de Investigación Biomédica en Red de Cáncer, Grupo Español de Investigación en Cáncer de Mama, Universidad Complutense, Madrid; Luis De la Cruz-Merino, Hospital Universitario Virgen Macarena, Seville, Spain; Gabe S. Sonke, Netherlands Cancer Institute/Borstkanker Onderzoek Groep Study Center, Amsterdam, the Netherlands; J. Thaddeus Beck, Highlands Oncology Group, Fayetteville, AR; Xavier Pivot, Institut Régional du Cancer, Strasbourg, France; Gena Vidam, Karen Rodriguez Lorenc, Michelle Miller, and Tetiana Taran, Novartis Pharmaceuticals, East Hanover, NJ; and Yingbo Wang, Novartis Pharma, Basel, Switzerland.

View Article and Find Full Text PDF
August 2018

The cost and cost trajectory of whole-genome analysis guiding treatment of patients with advanced cancers.

Mol Genet Genomic Med 2017 May 12;5(3):251-260. Epub 2017 Mar 12.

Canadian Centre for Applied Research in Cancer Control (ARCC)Cancer Control ResearchBC Cancer AgencyVancouverBritish ColumbiaCanada.

View Article and Find Full Text PDF
May 2017

Enhancing Endocrine Therapy Combination Strategies for the Treatment of Postmenopausal HR+/HER2- Advanced Breast Cancer.

Oncologist 2017 01 18;22(1):12-24. Epub 2016 Nov 18.

Division of Medical Oncology, Dalhousie University, and Atlantic Clinical Cancer Research Unit, Halifax, Nova Scotia, Canada.

View Article and Find Full Text PDF
January 2017

Basal biomarkers nestin and INPP4b identify intrinsic subtypes accurately in breast cancers that are weakly positive for oestrogen receptor.

Histopathology 2017 Jan 29;70(2):185-194. Epub 2016 Sep 29.

Department of Pathology and Laboratory Medicine, Genetic Pathology Evaluation Centre, University of British Columbia, Vancouver, BC, Canada.

View Article and Find Full Text PDF
January 2017

Correlation of baseline biomarkers with clinical outcomes and response to fulvestrant with vandetanib or placebo in patients with bone predominant metastatic breast cancer: An OCOG ZAMBONEY sub-study.

J Bone Oncol 2015 Jun 12;4(2):47-53. Epub 2015 Jun 12.

Program for Cancer Therapeutics, Ottawa Hospital Research Institute, Box 926, 501 Smyth Road, Ottawa, ON, Canada K1H 8L6 ; Department of Medicine, University of Ottawa, Ottawa, ON, Canada.

View Article and Find Full Text PDF
June 2015

Neoadjuvant and Adjuvant Therapy for HER2 Positive Disease.

Authors:
Stephen K Chia

Am Soc Clin Oncol Educ Book 2015 :e41-8

From the BC Cancer Agency, Vancouver, Canada.

View Article and Find Full Text PDF
February 2016

Defining breast cancer intrinsic subtypes by quantitative receptor expression.

Oncologist 2015 May 23;20(5):474-82. Epub 2015 Apr 23.

Lineberger Comprehensive Cancer Center and Department of Genetics, University of North Carolina, Chapel Hill, North Carolina, USA; Clinical Trials and Statistics Unit at The Institute of Cancer Research, London, United Kingdom; Servicio de Oncología Médica, Instituto de Investigacion Sanitaria Hospital Universitario Gregorio Marañón, Facultad de Medicina, Universidad Complutense, Madrid, Spain; Department of Pathology, University of British Columbia, Vancouver, British Columbia, Canada; Translation Genomics Unit, Vall d´Hebron Institute of Oncology, Barcelona, Spain; British Columbia Cancer Agency, Vancouver, British Columbia, Canada; Department of Medical Oncology, Hospital General Universitario de Elche, Alicante, Spain; Department of Medical Oncology, Instituto Valenciano de Oncologia, Valencia, Spain; National Cancer Institute of Canada Clinical Trials Group, Kingston, Ontario, Canada; Department of Medical Oncology, Hospital Universitario Virgen del Rocio, Seville, Spain; Department of Medical Oncology, Complejo Hospitalario Universitario A Coruña, Coruña, Spain; Department of Medical Oncology, Hospital Universitario Virgen de la Victoria, Málaga, Spain; GEICAM, Madrid, Spain; Sunnybrook Odette Cancer Centre, University of Toronto, Toronto, Ontario, Canada; McMaster University, Hamilton, Ontario, Canada; Department of Oncology, Tom Baker Cancer Centre, University of Calgary, Calgary, Alberta, Canada; Department of Pathology, University of Utah Health Sciences Center, Salt Lake City, Utah, USA; Department of Medicine, Washington University, St. Louis, Missouri, USA; Department of Oncology, Hospital of Prato, Istituto Toscani Tumori, Florence, Italy

View Article and Find Full Text PDF
May 2015

Dynamics of genomic clones in breast cancer patient xenografts at single-cell resolution.

Nature 2015 Feb 26;518(7539):422-6. Epub 2014 Nov 26.

1] Department of Molecular Oncology, BC Cancer Agency, 675 West 10th Avenue, Vancouver, British Columbia V5Z 1L3, Canada [2] Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia V6T 2B5, Canada [3] Michael Smith Genome Sciences Centre, Vancouver, British Columbia V5Z 1L3, Canada [4] Centre for Translational and Applied Genomics, BC Cancer Agency, 600 West 10th Avenue, Vancouver, British Columbia V5Z 4E6, Canada.

View Article and Find Full Text PDF
February 2015

Breast cancer in young women: have the prognostic implications of breast cancer subtypes changed over time?

Breast Cancer Res Treat 2014 Oct 11;147(3):617-29. Epub 2014 Sep 11.

BC Cancer Agency, Vancouver Cancer Centre, University of British Columbia, 600 W 10th Avenue, Vancouver, BC, V5Z 4E6, Canada,

View Article and Find Full Text PDF
October 2014

Stage, treatment and outcomes for patients with breast cancer in British Columbia in 2002: a population-based cohort study.

CMAJ Open 2013 Oct 7;1(4):E134-41. Epub 2013 Nov 7.

Breast Cancer Outcomes Unit, British Columbia Cancer Agency, Vancouver, BC ; Department of Radiation Oncology, Vancouver Centre, British Columbia Cancer Agency, Vancouver, BC.

View Article and Find Full Text PDF
October 2013

When is downstream pathway inhibition important?

Lancet Oncol 2014 May;15(6):541-2

Medical Oncology, British Columbia Cancer Agency, 600 West 10th Avenue, Vancouver, BC, V5Z 4E6, Canada. Electronic address:

View Article and Find Full Text PDF
May 2014

Mapping the FACT-G cancer-specific quality of life instrument to the EQ-5D and SF-6D.

Health Qual Life Outcomes 2013 Dec 1;11:203. Epub 2013 Dec 1.

Canadian Centre for Applied Research in Cancer Control, British Columbia Cancer Agency, Vancouver, BC, Canada.

View Article and Find Full Text PDF
December 2013

New agents in locally advanced breast cancer.

Curr Opin Support Palliat Care 2014 Mar;8(1):64-9

BC Cancer Agency, Vancouver, British Columbia, Canada.

View Article and Find Full Text PDF
March 2014

Cost-effectiveness of MRI for breast cancer screening in BRCA1/2 mutation carriers.

BMC Cancer 2013 Jul 10;13:339. Epub 2013 Jul 10.

Cancer Control Research, BC Cancer Agency, 675 W, 10th Ave, Vancouver, BC V5Z 1L3, Canada.

View Article and Find Full Text PDF
July 2013

IGF-1R inhibition: right direction, wrong pathway?

Lancet Oncol 2013 Mar 13;14(3):182-3. Epub 2013 Feb 13.

Medical Oncology, British Columbia Cancer Agency, 600 West 10th Avenue, Vancouver, BC, V5Z 4E6, Canada.

View Article and Find Full Text PDF
March 2013

Linking toxicity to the target.

J Clin Oncol 2012 Sep 30;30(25):3039-40. Epub 2012 Jul 30.

View Article and Find Full Text PDF
September 2012

Patients with metastatic breast cancer using bevacizumab as a treatment: is there still a role for it?

Curr Treat Options Oncol 2012 Jun;13(2):249-62

British Columbia Cancer Agency, University of British Columbia, Vancouver, BC, Canada.

View Article and Find Full Text PDF
June 2012

Testing for discordance at metastatic relapse: does it matter?

Authors:
Stephen Chia

J Clin Oncol 2012 Feb 30;30(6):575-6. Epub 2012 Jan 30.

View Article and Find Full Text PDF
February 2012

Molecular alterations between the primary breast cancer and the subsequent locoregional/metastatic tumor.

Oncologist 2012 20;17(2):172-8. Epub 2012 Jan 20.

Department of Medical Oncology, British Columbia Cancer Agency, University of British Columbia, 600 West 10th Avenue, Vancouver, British Columbia, Canada, V5Z 4E6.

View Article and Find Full Text PDF
June 2012

Don't pick the loser: lessons from the GeparQuinto trial.

Authors:
Stephen K Chia

Lancet Oncol 2012 Feb 17;13(2):112-3. Epub 2012 Jan 17.

Division of Medical Oncology, British Columbia Cancer Agency, 600 West 10th Avenue, Vancouver, BC V5Z 4E6, Canada.

View Article and Find Full Text PDF
February 2012

Chromosome 17 centromere (CEP17) duplication as a predictor of anthracycline response: evidence from the NCIC Clinical Trials Group (NCIC CTG) MA.5 Trial.

Breast Cancer Res Treat 2012 Jan 1;131(2):541-51. Epub 2011 Nov 1.

Sunnybrook Odette Cancer Centre, The University of Toronto, 2075 Bayview Avenue, Toronto, ON M4N 3M5, Canada.

View Article and Find Full Text PDF
January 2012

With maturity comes confidence: EBCTCG tamoxifen update.

Lancet 2011 Aug 28;378(9793):747-9. Epub 2011 Jul 28.

British Columbia Cancer Agency, University of British Columbia, Vancouver, BC, Canada V5Z 4E6.

View Article and Find Full Text PDF
August 2011

Trends in improving survival in breast cancer: two steps forward but one step back?

Authors:
Stephen Chia

Breast Cancer Res Treat 2011 Aug 12;128(3):807-9. Epub 2011 Apr 12.

British Columbia Cancer Agency, Vancouver, Canada.

View Article and Find Full Text PDF
August 2011

What is the difference between triple-negative and basal breast cancers?

Cancer J 2010 Jan-Feb;16(1):12-6

Department of Medical Oncology, BC Cancer Agency, University of British Columbia, Vancouver, BC, Canada.

View Article and Find Full Text PDF
May 2010

Challenging the dogma on trastuzumab: a matter of the heart.

Lancet 2010 Jan;375(9712):349-50

Division of Medical Oncology, British Columbia Cancer Agency, Vancouver, BC, Canada V5Z 4E6.

View Article and Find Full Text PDF
January 2010

Encapsulated apocrine papillary carcinoma of the breast--a tumour of uncertain malignant potential: report of five cases.

Virchows Arch 2009 Dec 28;455(6):477-83. Epub 2009 Oct 28.

The Department of Medical Oncology, British Columbia Cancer Agency, Vancouver, Canada.

View Article and Find Full Text PDF
December 2009

Predicting benefit from fulvestrant in pretreated metastatic breast cancer patients.

Breast Cancer Res Treat 2009 Nov 24;118(2):377-83. Epub 2009 Jun 24.

Division of Medical Oncology, Princess Margaret Hospital, Suite 5-205, 610 University Avenue, Toronto, ON, M5G 2M9, Canada.

View Article and Find Full Text PDF
November 2009

Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer.

J Natl Cancer Inst 2009 May 12;101(10):736-50. Epub 2009 May 12.

Genetic Pathology Evaluation Centre, Vancouver Coastal Health Research Institute, British Columbia Cancer Agency, and University of British Columbia, Vancouver, BC, Canada.

View Article and Find Full Text PDF
May 2009

Progesterone receptor is a significant factor associated with clinical outcomes and effect of adjuvant tamoxifen therapy in breast cancer patients.

Breast Cancer Res Treat 2010 Jan 10;119(1):53-61. Epub 2009 Feb 10.

Genetic Pathology Evaluation Centre at Vancouver General Hospital, Prostate Center, University of British Columbia, Vancouver, BC, Canada.

View Article and Find Full Text PDF
January 2010

Phase II trial of OGX-011 in combination with docetaxel in metastatic breast cancer.

Clin Cancer Res 2009 Jan;15(2):708-13

Division of Medical Oncology, British Columbia Cancer Agency, University of British Columbia, 600 West 10th Avenue, Vancouver, British Columbia, Canada V5Z 4E6.

View Article and Find Full Text PDF
January 2009

Safety, pharmacokinetics, and efficacy of CPX-1 liposome injection in patients with advanced solid tumors.

Clin Cancer Res 2009 Jan;15(2):692-700

Segal Cancer Center, Sir Mortimer B. Davis Jewish General Hospital, Department of Oncology, McGill University, Montreal, Quebec, Canada.

View Article and Find Full Text PDF
January 2009

Human epidermal growth factor receptor 2 overexpression as a prognostic factor in a large tissue microarray series of node-negative breast cancers.

J Clin Oncol 2008 Dec 10;26(35):5697-704. Epub 2008 Nov 10.

Division of Medical Oncology, Breast Cancer Outcomes Unit, British Columbia Cancer Agency, University of British Columbia, Vancouver, British Columbia, Canada.

View Article and Find Full Text PDF
December 2008

Fulvestrant: expanding the endocrine treatment options for patients with hormone receptor-positive advanced breast cancer.

Breast 2008 Apr 18;17 Suppl 3:S16-21. Epub 2008 Mar 18.

Division of Medical Oncology, British Columbia Cancer Agency, University of British Columbia, 600 West 10th Avenue, Vancouver, BC, V5Z 4E6, Canada.

View Article and Find Full Text PDF
April 2008

Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype.

Clin Cancer Res 2008 Mar;14(5):1368-76

Genetic Pathology Evaluation Centre, Vancouver Coastal Health Research Institute, British Columbia Cancer Agency, and University of British Columbia, Vancouver, British Columbia, Canada.

View Article and Find Full Text PDF
March 2008

Locally advanced and inflammatory breast cancer.

J Clin Oncol 2008 Feb;26(5):786-90

Department of Medical Oncology, British Columbia Cancer Agency, 600 West 10th Ave, Vancouver, British Columbia, Canada.

View Article and Find Full Text PDF
February 2008

Method of detection of new contralateral primary breast cancer in younger versus older women.

Clin Breast Cancer 2007 Aug;7(9):705-9

Regional Cancer Program, Northeastern Ontario Regional Cancer Centre, Sudbury Regional Hospital, Ontario, Canada.

View Article and Find Full Text PDF
August 2007

The impact of new chemotherapeutic and hormone agents on survival in a population-based cohort of women with metastatic breast cancer.

Cancer 2007 Sep;110(5):973-9

Division of Medical Oncology, British Columbia Cancer Agency and the University of British Columbia, Vancouver and Victoria, British Columbia, Canada.

View Article and Find Full Text PDF
September 2007